Main Content

The Chandler Project

The Chandler Project provides those affected by achondroplasia with the latest in scientific research and development + pharmaceutical, and surgical treatment options.

The 501(c)(3) founded by Chandler Crews in 2018 provides achondroplasia patients, caregivers, physicians and the community as a whole access to the latest news and top resources when searching for the best treatment options to fit the patient's needs.

Since 2019, The Chandler Project has hosted the only conference in North America that brings together patients, caregivers, world-renowned physicians, and pharmaceutical companies to engage and network with one another on the topic of treatment options for achondroplasia.

Photo – L to R: Ilya Nudelman, orthopedic device sales representative; Chandler Crews, achondroplasia patient & founder of The Chandler Project; Shawn C. Standard, MD, FAAOS, Head of Pediatric Orthopedics at the International Center for Limb Lengthening, at the first Achondroplasia Research Conference in Baltimore, MD – 2019.

The Chandler Project brings you three of the most important key elements that achondroplasia patients & their caregivers want when searching for treatment options:

Awareness

Support

Advocacy

News

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. The 52-week

Read More

touchEXPERT OPINIONS Clinical management strategies in achondroplasia: Current landscape and new horizons

via touchEndocrinology. Watch three leading experts explore how the pathophysiology of achondroplasia is being targeted by new and emerging pharmacotherapies to restore endochondral ossification. A roadmap to optimized current and future clinical management is also outlined. Clinical management strategies in achondroplasia: Current landscape and new horizons Clinical management strategies in achondroplasia: Current landscape and new

Read More

Search

Close (esc)